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HIV-1 often invades the CNS during primary infection, eventually resulting in neurological disorders in up to
50% of untreated patients. The CNS is a distinct viral reservoir, differing from peripheral tissues in immuno-
logical surveillance, target cell characteristics and antiretroviral penetration. NeurotropicHIV-1 likely develops
distinct genotypic characteristics in response to this unique selective environment.We sought to catalogue the
genetic features of CNS-derived HIV-1 by analysing 456 clonal RNA sequences of the C2-V3 env subregion
generated from CSF and plasma of 18 chronically infected individuals. Neuropsychological performance of all
subjects was evaluated and summarized as a global deficit score. A battery of phylogenetic, statistical and
machine learning tools was applied to these data to identify genetic features associated with HIV-1 neurotrop-
ism and neurovirulence. Eleven of 18 individuals exhibited significant viral compartmentalization between
blood and CSF (P < 0.01, Slatkin–Maddison test). A CSF-specific genetic signature was identified, comprising
positions 9, 13 and 19 of the V3 loop. The residue at position 5 of the V3 loop was highly correlated with
neurocognitive deficit (P < 0.0025, Fisher’s exact test). Antibody-mediated HIV-1 neutralizing activity was
significantly reduced in CSF with respect to autologous blood plasma (P < 0.042, Student’s t-test). Accordingly,
CSF-derived sequences exhibited constrained diversity and contained fewer glycosylated and positively
selected sites. Our results suggest that there are several genetic features that distinguish CSF- and plasma-
derived HIV-1 populations, probably reflecting altered cellular entry requirements and decreased immune
pressure in the CNS. Furthermore, neurological impairment may be influenced by mutations within the viral
V3 loop sequence.
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Introduction
HIV-1 and simian immunodeficiency virus (SIV) cross
the blood–brain barrier during primary infection,
eventually resulting in neurological complications in up to
50% of untreated individuals (Ho et al., 1985; Grant et al.,
1987; Heaton et al., 1995; Price, 1996; Zink et al., 1999;
Pierson et al., 2000; Clements et al., 2002). HIV-associated
dementia, encephalopathy and sensory neuropathies contri-
bute significantly to morbidity and mortality (McArthur
et al., 2003). In addition, the CNS may serve as a sanctuary
site for long-term viral persistence due to the suboptimal
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penetration of several antiretroviral agents (Misra et al.,
2003).
The CNS is a distinct viral reservoir, differing from per-
ipheral tissues in immunological surveillance, cytokine
milieu, target cell characteristics and antiretroviral penetra-
tion. Evidence from humans and chimpanzees suggests that
selective pressure from anti-HIV neutralizing antibodies and
cytotoxic T cells may be diminished in the brain and CSF
(Goudsmit et al., 1987; Ljunggren et al., 1989; von Gegerfelt
et al., 1992; Ruta et al., 1998; Pachter et al., 2003; Song et al.,
2004). Cytokines such as CXCL12, interleukin-6, tumour
necrosis factor-alpha and RANTES that modulate HIV repli-
cation may differ in relative concentrations between the CSF
and blood plasma (Gonzalez-Scarano and Martin-Garcia,
2005). The predominant targets of HIV-1 infection in the
CNS are brain-derived macrophages and microglial cells,
rather than the CD4+ lymphocytes that serve as targets in
the periphery (Gartner et al., 1986). Several antiretroviral
drugs do not efficiently cross the blood–brain barrier, pos-
sibly limiting the suppression of viral replication in the CNS
(Staprans et al., 1999; Misra et al., 2003).
The uniqueness of the CNS environment is often reflected
in compartment-specific HIV-1 genotypic and phenotypic
characteristics. Contemporaneous CNS- and blood-derived
viruses are frequently compartmentalized on the basis of
phylogenetic analysis of intrapatient sequences (Korber et al.,
1994; Power et al., 1995; Hughes et al., 1997; Wong et al.,
1997; Gorry et al., 2001; Ohagen et al., 2003; Strain
et al., 2005; McCrossan et al., 2006), and brain-derived
env sequences may share signature mutations across indivi-
duals (Korber et al., 1994; Power et al., 1994). Differences in
CD4 dependence, co-receptor usage phenotype and LTR
sequence have been observed between brain- and blood-
derived HIV isolates, reflecting differences in chemokine
receptor expression and transcriptional environment
between microglia and peripheral host cells (Shieh et al.,
1998; Ross et al., 2001; Argyris et al., 2003; Hogan et al.,
2003; Zhou et al., 2003; Burdo et al., 2004). The presence of
discordant drug-resistance mutations in CSF and plasma
viral populations probably results from tissue-specific varia-
tion in drug efficacies due to the poor penetration of certain
antiretroviral agents (Wong et al., 1997; Cunningham et al.,
2000; Venturi et al., 2000; Cinque et al., 2003; Strain et al.,
2005). Moreover, recent evidence suggests that the evolution
of resistance may differ between brain subcompartments
(Smit et al., 2004).
HIV-1 RNA is detectable in the CSF of most infected
individuals throughout disease. Owing to the obvious
sampling difficulties associated with brain tissue, CSF
virus has often been investigated as a proxy for brain-derived
HIV-1 (studies of brain virus are almost exclusively limited
to post-mortem samples). This indirect sampling strategy is
supported by phylogenetic evidence that CSF and brain-
derived viral populations are more closely related to each
other than with populations derived from bone marrow,
kidney, liver, lung, lymph nodes and spleen (Sanjuan et al.,
2004). We previously described a high frequency of discor-
dant patterns of HIV drug resistance and partitioning of
C2-V3 env sequences from 18 matched CSF and plasma
samples (Strain et al., 2005). Here, we performed a more
detailed analysis of these clonal sequences to catalog the
genetic and evolutionary features that distinguish CSF- and
blood plasma-derived HIV-1 populations. In addition, the
extent of HIV neutralizing activity conferred by CSF and
plasma from five chronically infected individuals within
this cohort was measured using an in vitro assay to compare
and contrast the immunological conditions in these two
tissue compartments. Finally, we investigated the genetic
basis of neurovirulence by comparing CSF-derived sequences
from several individuals with known global deficit scores
(GDS) based on a comprehensive neuropsychological evalua-
tion. Our analysis suggests that HIV-1 neurotropism and
neurovirulence in chronically infected individuals are
modulated by residues in and around the V3 loop subregion
of the viral envelope, and, moreover, attenuated immune
surveillance in the CNS may contribute to the discordant
evolutionary patterns observed in CSF- and plasma-derived
HIV-1 populations.
(Presented in part at the 6th International Symposium on
Neurovirology, Sardinia, Italy, September 2004.)
Material and methods
Subjects
Twenty-one individuals enrolled in clinical studies at the HIV
Neurobehavioral Research Center (HNRC) between 1998 and
2002 were initially examined. All subjects had stable or no antiviral
therapy for at least 2 months before the study, had plasma and CSF
HIV RNA of >500 copies/ml and had no evidence of systemic or
CNS opportunistic infections or malignancy based on clinical,
laboratory and/or neuroimaging studies. Data were available on
past and present therapy, current HIV RNA and CD4 counts,
nadir CD4 counts and CSF cell counts (Table 1). All studies
were conducted in compliance with local institutional review
board (IRB) guidelines and with subjects’ written informed consent.
Specimen processing
Paired blood from peripheral venipuncture in acid citrate dextrose
(ACD) tubes and CSF from lumbar punctures were collected (typi-
cally collected within 1 h of each other) and processed within 2 h of
collection. Plasma and cell-free CSF were aliquoted, frozen and
stored at 70C until processing. All subsequent plasma and
CSF processing was performed separately to minimize the within-
subject cross-contamination of samples.
Nucleotide sequencing
Sequencing methods were previously described in full (Strain et al.,
2005). In brief, reverse transcription and polymerase chain reaction
(PCR) amplification of C2-V3 env for each sample was performed
in triplicate or quadruplicate using the Finnzyme one-step RT–PCR
kit (MJ Research, Waltham, MA, USA) and primers V3Fout and
V3Bout as described previously in a 25 ml reaction volume. About
2.5 ml of first-step RT–PCR product was used in the second, nested
PCR reaction with primers V3Fin and V3Bin (Strain et al., 2005).
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All assays included negative controls and were conducted in con-
ditions to minimize the potential for PCR contamination utilizing
aerosol-resistant pipet tips, dedicated PCR reagents and laminar
flow hoods. Replicate PCR products were proportionately pooled
and cloned using the TOPO-TA cloning system (Invitrogen,
Carlsbad, CA, USA). Purified plasmids were sequenced in both
directions with 20M13 primer (50-gtaaaacgacggccag-30) and Topo
Forward primer (50-tggatatctgcagaattcg-30) using Prism Dye termi-
nator kits (ABI, Foster City, CA, USA) on an ABI 3100 Genetic
Analyzer. Sequences were compiled, aligned and edited using
Sequencher 4.0 (Genecodes, Ann Arbor, MI, USA) and Clustal
(version 1.81).
Neuropsychological assessment
Subjects completed a detailed neuropsychological assessment
measuring their functioning in eight cognitive ability domains:
verbal functioning, abstraction, complex perceptual-motor skills,
attention, learning, memory, motor skills and sensory functioning.
Test results were summarized as ‘deficit scores’, which reflect the
number and severity of impaired performances throughout the test
battery and give relatively less weight to test performances within or
above the average range. A GDS is computed by adding the deficit
ratings of the component test measures and dividing by the
total number of measures. Deficit scores are sensitive to the pre-
sence and pattern of NP impairments in HIV+ individuals (Heaton
et al., 1995). Statistical classification of NP impaired/NP normal was
made through the use of a GDS cut-off score that demonstrates high
accuracy in predicting clinician ratings of NP status. A GDS of
0.5 or greater is considered to be in the impaired range. This
represents at least mild impairment on half of the tests of the
NP battery (Carey et al., 2004).
Phylogenetic reconstruction
Initial multiple sequence alignments were generated using ClustalX
(Thompson et al., 1994), with default gap parameters and the ‘IUB’
DNA weight matrix. Subsequent manual aligning was performed
using the Se–Al sequence alignment editor (Rambaut, 1996; http://
evolve.zoo.ox.ac.uk/). Phylogenies describing sequences from each
individual host were built using FastDNAml (Olsen et al., 1994),
estimating base frequencies from the data, Ts/Tv ratio of 2.0. Diver-
sity measurements were calculated using dnadist and protdist
(Felsenstein, 1993). A master tree describing the entire data set
was built by implementing dnadist and neighbor within the Phylip
3.5c package (Felsenstein, 1993) using the F84 model, gamma dis-
tributed rates across sites and Ts/Tv ratio of 2.0. Trees were viewed
using TreeView X (Page, 1996).
Evaluation of compartmentalization
The degree of segregation between compartments was assessed
by testing for panmixis using gene phylogenies (Slatkin and
Maddison, 1989; Hudson et al., 1992) as implemented in MacClade
(Sinauer, Sunderland, MA, USA). In brief, the minimum possible
number of inter-compartment migration events was tallied, on the
basis of the maximum likelihood trees for each individual subject’s
C2-V3 sequences and their characterization according to compart-
ment of origin. This result was compared with the distribution of
migration events in 1000 trees in which the taxa have been ran-
domly shuffled across tips, retaining the original topology and
associated polytomies (Nickle et al., 2003b). Evidence of restricted
gene flow (compartmentalization) was documented when <1%of the
randomized trees required the same or a fewer number of migration
events as for the sample data (Slatkin and Maddison, 1989).
Table 1 Subject characteristics
Patient CSF HIV-1 RNA
(log copies/ml)
Plasma HIV-1
RNA (log copies/ml)
Current CD4
(cells/mm3)
Nadir CD4
(cells/mm3)
NP GDS Any Rx Current Rx
A 4.5 4.9 355 133 1.28 + 
B 5.2 5.5 219 112 2.13 + +
C 5.2 5.7 312 312 0.44  
D 4 5.9 55 23 0.69 + 
E 4 4.7 277 277 1.41 + 
F 4.8 4.7 688 391 0.88 + +
H 4.3 4.9 267 248 0.53 + 
I 4.6 6 112 112 NA + 
J 6.2 5.2 153 153 0.75  
K 4.4 5.7 221 221 0.5  
L 3.2 6 32 10 0.63 + +
M 3.8 5.2 91 91 0.56 + +
N 4.6 4.5 145 145 0.31 + +
O 3.3 5.6 43 30 1.4  
P 3.2 5.9 60 56 1.18 + 
Q 3.5 5.1 68 68 0.94 + 
R 2.9 5.1 16 16 3.5 + +
S 3.2 6 32 32 2.88 + 
Median 4.15 5.35 128.5 112 0.88
NA = not available; any Rx = past or present antiretroviral therapy; current Rx = on antiretroviral therapy at time of sampling or within 2months
of sampling (adapted from Strain et al., 2005).
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Machine learning classification
All classification experiments in this analysis were conducted using
WEKA (Waikato Environment for Knowledge Analysis), an
open-source collection of data processing and machine learning
algorithms (Witten and Frank, 2000). The J48 decision tree inducer,
based on the C4.5 algorithm (Quinlan, 1993), was implemented
with the parameter ‘MinNumObj’ set at a value of 11 to limit the
complexity of theories and minimize the risk of over-fitting.
Classifiers were evaluated using 100 iterations of stratified 10-
fold cross-validation, a procedure designed to conservatively reflect
the performance of classification models on novel data sets (Witten
and Frank, 2000).
Analysis of selection
We used a procedure described by Leigh Brown et al. (A. J. Leigh
Brown, S. L. Kosakovsky Pond, Z. Grossman, D. D. Richman,
S. D. Frost, submitted for publication) to test for differential selec-
tive pressure on a given codon in two populations. First, branch
lengths and nucleotide substitution biases under an appropriate
nucleotide substitution model are inferred from the entire align-
ment. Secondly, holding these parameters constant, a version of the
MG94xREV codon model (http://mbe.oxfordjournals.org/cgi/
content/abstract/msi232v1) is used to estimate synonymous (as)
and non-synonymous substitution rates ðbLs Þ at each codon s inde-
pendently in sequences from two different populations. We say that
differential evolution has acted on codon s when vs ¼ bs/as differs
significantly between two populations. Formally,
H0 : b
1
s ¼ Ra1s and b2s ¼ Ra2s No differential evolution
HA : b
1
s ‚a
1
s ‚b
2
s ‚a
2
s Differential evolution
Significance of the difference can be assessed by assuming
the x21 distribution for the likelihood ratio. This test is con-
servative, but has a high positive predictive value (>95%)
based on simulated data (Kosakovsky Pond and Frost,
2005; A. J. Leigh Brown, S. L. Kosakovsky Pond, Z. Grossman,
D. D. Richman, S. D. Frost, submitted for publication).
Analysis of glycosylation
GlycoTracker.pl (S. K. Pillai, unpublished data) was used to identify
N-linked glycosylation sites within each sequence. The perl script
provides a tally of all glycosylation sites, along with their respective
locations (numbered according to HXB2 gp160). We compared the
extent and distribution of N-linked glycosylation across the C2-V3
region in both compartments by identifying ‘N[X]S’ and ‘N[X]T’
motifs in plasma- and CSF-derived sequences (Marshall, 1974).
Neutralization assay
Antibody-mediated neutralization of HIV-1 was measured using a
previously described recombinant virus assay (Richman et al.,
2003). Neutralizing activity present in plasma was compared
with that in CSF against prototypic lymphocytotropic (NL4-3)
(Adachi et al., 1986) and macrophage-tropic (JR-CSF) (Koyanagi
et al., 1987) HIV strains. Standardized inocula of recombinant,
luciferase expressing viral constructs pseudotyped with NL4-3 or
JR-CSF Env were incubated with serial dilutions of either CSF or
plasma collected from the same time point. Infection of U87 cells
transduced to express CD4/CXCR4/CCR5 yields a luminescent
read-out that is inversely proportional to the neutralizing activity
in the study fluid. To exclude non-neutralizing antibody-mediated
inhibition by other substances such as antiviral drugs, parallel
experiments were performed with ampho-MuLV pseudotyped
virus as described previously (Richman et al., 2003).
Survey of publicly available sequence data
All available CSF-derived subtype B V3 loop sequences with accom-
panying patient identification information were downloaded from
the Los Alamos National Lab HIV Sequence Database. A majority-
rule consensus sequence was generated for each patient’s sequence
data. CSF-derived consensus sequences were compared against all
available peripheral V3 loop sequences in the Los Alamos subtype B
web alignment (which contains one single representative sequence
per patient).
Statistical analysis
The following non-parametric tests were applied to these data, as
implemented in JMP version 5.1 (SAS Institute, Cary, NC, USA):
Mann–Whitney U-test, Wilcoxon signed-rank test and Fisher’s
exact test.
Nucleotide sequence accession numbers
The C2-V3 env sequences were submitted to GenBank and assigned
accession numbers DQ143360 to DQ143815.
Results
Compartmentalization of CSF-derived
virus
Nucleotide sequences representing CSF- and plasma-derived
viruses were successfully generated for 18 out of 21 indivi-
duals initially enrolled in this study (Table 1). A total of 456
clonal CSF and plasma env sequences were generated and
analysed to determine the genetic characteristics of CSF-
derived HIV-1. We evaluated the compartmentalization of
contemporaneous CSF- and plasma-derived sequences by
applying a modified version of the parsimony-based cladistic
method of Slatkin and Maddison (1989) to maximum like-
lihood phylogenetic reconstructions (Nickle et al., 2003a, b).
According to this stringent test of panmixis, 11 of 18 indi-
viduals (individuals A, F, H, J, M-S) in this cohort exhibited
independent clustering of tissue-specific populations (P <
0.01), while 2 of the remaining 7 individuals (B, L) har-
boured variants that exhibited partial compartmentalization
between tissues (0.01 < P < 0.05) (Fig. 1).
Amino acid diversity in plasma- and
CSF-derived viral populations
We next calculated the amino acid diversity of C2-V3
sequences from CSF and plasma, focusing on average
pairwise distances derived using the Dayhoff PAM substitu-
tion matrix (Dayhoff et al., 1978). There was no significant
difference in overall protein diversity between CSF- and
plasma-derived sequences pooled across all 18 individuals
(data not shown). When focusing exclusively on the V3
loop subregion, however, there was a significant reduction
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of diversity in CSF-derived sequences (P < 0.05, Wilcoxon
signed rank) (Fig. 2). Tissue-specific patterns of diversity
did not differ between compartmentalized and non-
compartmentalized individuals.
CSF-specific Env genetic signature
CSF-derived viruses may share genetic characteristics across
individuals due to tissue-specific selective pressures that are
common across hosts. We employed a previously described
machine learning approach to look for evidence of a genetic
signature shared by CSF-derived sequences pooled across
individuals (Pillai et al., 2005). The training data for this
experiment drew samples from the entire available sequence
set, consisting of 231 plasma sequences and 225 from CSF.
Our results (data not shown) indicated that there was no
evidence of a signature, on the basis of the high error rate
associated with the classification trial; tissue tropism was
misclassified in nearly 50% of test cases. However, when
we limited our analysis to the 94 plasma and 130 CSF
sequences associated with the 11 compartmentalized
individuals (A, F, H, J, M-S), classification accuracy
(conservatively estimated using a cross-validation proce-
dure) increased dramatically to 87%. The genetic signature
underlying the classification model consisted of positions 5,
9, 13 and 19 of the V3 loop (HXB2 gp160 positions 300, 304,
308 and 314, respectively) (Supplementary Fig. 1). The pre-
sence of proline or histidine at V3 loop position 13 (gp160
position 308) was significantly correlated with compartmen-
talization in the CSF (P < 0.044, Fisher’s exact test). In
addition, the highest net difference in site-specific variability
between CSF and plasma (as measured by Shannon entropy)
was observed at V3 loop position 13 (Supplementary Fig. 2).
Compartmental differences in relative amino acid composi-
tion at these signature sites are evident in Env alignments of
each individual’s sequences (Supplementary Fig. 3) and in
(pooled) consensus sequence logos (Fig. 3). To assess
whether the signatures identified here could be generalized
to independent data sets, we performed a survey of publicly
available subtype B sequences in the Los Alamos HIV
Sequence Database. This analysis supported our earlier
observations; the frequency of histidine or proline at position
13 of the V3 loop was significantly higher in CSF-derived
Fig. 1 Examples of compartmentalized and non-compartmentalized viral populations. Maximum likelihood phylogenies of C2-V3
env sequences. Red circles = individual L (non-compartmentalized virus), and blue circles = individual N (compartmentalized virus).
Open circles represent CSF sequences, and closed circles indicate plasma-derived sequences. Strains ADA, NY5, JRFL and SF162
included as outgroups.
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sequences (P < 0.048, Fisher’s exact test). CSF-derived con-
sensus sequences from 75% of patients (21 of 28) with avail-
able CSF sequence data contained either histidine or proline
at position 13. Conversely, only 56.5% of peripheral
sequences (100 of 177) contained either of these residues
at position 13 (data not shown).
Identification of discordantly selected sites
We used a maximum likelihood approach to identify
codons within env that were under discordant selection
pressure in CSF and plasma. Selection pressure is described
as the ratio between non-synonymous substitutions per
non-synonymous site (dN) and synonymous substitutions
per synonymous site (dS) (Nei and Gojobori, 1986). A
total of seven sites in the C2-V3 region exhibited discordant
levels of selection pressure (dN/dS) in CSF and plasma, based
on a differential P-value cut-off of 0.1 (Table 2). Five out of
these seven sites were under strong negative selection in CSF
while corresponding sites were under positive selection or
evolving neutrally in blood plasma (Table 2). These data are
in alignment with our compartment-specific maximum like-
lihood estimates of global dN/dS across the C2-V3 region.
CSF-derived HIV-1 sequences exhibited considerably lower
dN/dS values than plasma-derived sequences (data not
shown).
N-linked glycosylation in plasma- and
CSF-derived viral populations
We next examined N-linked glycosylation patterns across
the C2-V3 env subregion, which are believed to vary in
Fig. 2 V3 amino acid diversity in CSF- and blood-derived viral populations. Diversity was significantly lower in CSF-derived viral populations
across individuals (P < 0.01, Wilcoxon test). Green circles indicate compartmentalized individuals. Vertical bars represent standard error.
A
B
Fig. 3 Consensus V3 loop sequences of (A) CSF and (B) plasma. The overall height of each position is proportional to its conservation.
Relative height of each amino acid reflects its prevalence at that site. The prevalence of proline and histidine at position 13 is
significantly higher in CSF sequences.
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response to selection pressure from the neutralizing antibody
response (Wei et al., 2003; Derdeyn et al., 2004; Chohan et al.,
2005). Our analysis revealed that extent of glycosylation,
reported as average number of glycosylation sites (sequons)
per sequence, tended to be lower in CSF-derived viruses,
although this trend was not quite significant (P < 0.062,
Wilcoxon signed rank) (Fig. 4). Virus from 7 out of 11
compartmentalized individuals exhibited significantly differ-
ent levels of glycosylation between compartments (P < 0.05,
Mann–Whitney), and 5 out of these 7 had lower numbers of
sequons in CSF-derived sequences (Fig. 4).
Antibody-mediated neutralization of
HIV-1 by CSF and plasma
The HIV-1 neutralizing activity of CSF and plasma
was measured to evaluate the hypothesis that reduced
glycosylation of CSF-derived viruses resulted from
attenuated local immune surveillance. This exploratory
data involved six individuals in our cohort (B, H, J, M,
N, and O), selected on the basis of discordant tissue-
specific glycosylation patterns and availability of specimens
to perform the neutralization assays. Neutralizing activity
against HIV-1 NL4-3 and JR-CSF was measured using a
previously described recombinant virus assay (Richman
et al., 2003). Data associated with individual B were
excluded from analysis owing to non-specific neutralizing
activity of residual antiretroviral drug in the plasma
(data not shown). In all cases, antibody-mediated neutrali-
zation of HIV-1 was significantly greater in blood plasma
(P < 0.042, Student’s t-test), in accordance with the viral
glycosylation data (Fig. 5). Neutralizing activity in CSF
was below the background of detection in the majority of
cases.
Table 2 Sites within env C2-V3 under differential selective pressure in plasma and CSF
HXB2 env position CSF (dN/dS) Plasma (dN/dS) Differential P-value Transition type
249 0.0000/1.5313 0.1499/0.0000 0.0923 Negative!neutral
250 0.0000/0.8244 0.1313/0.0000 0.0947 Negative!neutral
251 0.2539/0.0000 0.0000/1.3152 0.0499 Neutral!negative
255 0.0000/2.0299 0.4633/1.6224 0.0795 Negative!neutral
286 0.0000/0.8520 1.1051/0.0000 0.0131 Negative!positive
330 0.0000/3.2736 0.3629/0.9094 0.0694 Negative!neutral
346 1.5486/0.0000 0.9555/0.4798 0.092 Positive!neutral
Fig. 4 Extent of glycosylation (number of N-linked glycosylation sites) in CSF- and plasma-derived C2-V3 sequences. Green circles indicate
compartmentalized individuals. Red asterisks indicate significant differences between compartments (P < 0.05, Mann–Whitney). Whisker
bars represent standard error. Seven out of 11 compartmentalized individuals have significantly different numbers of glycosylation sites
in CSF- and plasma-derived sequences, and 5 out of those 7 have greater numbers in plasma populations.
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Correlation between env sequence and
neurovirulence
All of the subjects involved in this study underwent a com-
prehensive neuropsychological assessment measuring their
functioning in a variety of cognitive ability domains. Test
results were summarized as ‘deficit scores’, which reflect the
number and severity of impaired performances throughout
the test battery. GDS in this cohort ranged from 0.31
(normal) to 3.5 (moderate to severe impairment)
(Table 3). We looked for correlations between HIV-1 env
sequence and cognitive deficit scores using machine
learning-based regression analysis. The residue at position
5 of the V3 loop (HXB2 gp160 position 300) was the stron-
gest predictor of GDS. Specifically, the presence of serine at
position 5 was significantly correlated with topmost quartile
GDS (P < 0.0025, Fisher’s exact test) (Table 3).
Discussion
The results of our investigation reveal that the genetics of
CSF- and blood plasma-derived strains of HIV-1 differ on
several levels, confirming previous reports that HIV-1 within
the CNS can differ from virus in peripheral tissues. This
study extends those observations by cataloguing the CSF-
specific population genetic features of the HIV-1 quasi-
species. First, the CNS (as represented by CSF) functions
as a viral compartment in most, but not all, infected
individuals. Secondly, sequence diversity of the V3 loop
env subregion measured at the amino acid level is reduced
in CSF-derived viral populations. Thirdly, there is a CSF-
specific HIV-1 genetic signature associated with sequences
from compartmentalized individuals comprising four sites
within the V3 loop region. Fourth, several sites in the
viral envelope are under different levels of selective con-
straint in CSF and plasma, and exhibit discordant levels
of entropy in these tissues. Lastly, CSF-derived viruses
tend to be less glycosylated than blood-derived viruses,
probably reflecting the near lack of HIV neutralizing activity
in CSF.
Viral compartments are characterized by a restriction of
gene flow between cells or tissues, usually identified by phy-
logenetic analysis (Nickle et al., 2003a; Pillai et al., 2005). If
Fig. 5 Neutralization activity in CSF and plasma against prototypic lymphocytotropic and macrophage-tropic HIV-1 strains.
(A) Neutralization activity against NL4-3, (B) neutralization activity against JR-CSF. Asterisks indicate responses below the assay’s
limit of detection. No significant neutralization of AMV Env pseudotyped virus was seen for these patients’ sera, verifying that these
responses are against HIV env (data not shown).
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the CSF represents a distinct viral compartment, contem-
poraneous CSF- and plasma-derived sequences are expected
to cluster independently in a phylogenetic tree. We pre-
viously looked for evidence of compartmentalization
between CSF and blood plasma (Strain et al., 2005) by
applying the parsimony-based cladistic method of Slatkin
and Maddison (1989) to phylogenetic reconstructions.
Inter-population gene flow may be underestimated by this
approach, however, owing to the potential loss of polytomies
in the randomly generated trees used to evaluate statistical
significance (Nickle et al., 2003a). We circumvented this
issue by modifying the Slatkin–Maddison test; we generated
1000 random trees in which the taxa have been randomly
shuffled across tips, retaining the original topology and
associated polytomies. The results of this more conservative
test of panmixis did not conflict with our original findings.
Viral compartmentalization between blood and the CNS was
identified in 13 out of 18 individuals. Viral migration across
the blood–brain barrier was minimal and infrequent in these
individuals, which reinforces the concept that a significant
fraction of virus sampled in CSF is produced locally in the
CNS (Sanjuan et al., 2004). We looked for a clinical predictor
of HIV-1 compartmentalization (e.g. current CD4 count),
but failed to find any significant correlations, perhaps owing
to limited sample size. Two comparisons were on the verge
of significance, however; drug treatment and high CSF viral
load (>104 copies/ml) were associated with phylogenetic par-
titioning of env sequences (P < 0.09, and P < 0.10, respec-
tively; Fisher’s exact test).
CSF-derived V3 loop sequences were under stronger
negative selection and exhibited reduced levels of amino
acid diversity in comparison with blood-derived sequences.
These genetic characteristics probably reflect constraints
associated with tissue-specific cellular entry determinants
and reduced immune selection pressure in the CNS
(Shieh et al., 1998; Argyris et al., 2003; Pachter et al.,
2003). A low viral effective population size in the CNS
may contribute to the reduced diversity as well (Leigh
Brown, 1997), although potential sampling effects resulting
from lower CSF RNA copy numbers cannot be entirely
excluded. Tissue-specific cellular entry may be influenced
by HIV-1 co-receptor usage phenotype, which is largely
determined by the amino acid sequence and net charge of
the V3 loop (Pillai et al., 2003). We computed net charge
and predicted the co-receptor usage phenotype of these
viruses using a machine learning algorithm (Pillai et al.,
2003), but did not observe any correlation between tissue
of origin and co-receptor preference; CCR5 usage was nearly
universal across compartments and individuals (data not
shown, see Supplementary Fig. 4). To pursue the reduced
immune selection hypothesis, we examined the N-linked
glycosylation patterns across the C2-V3 env subregion and
measured the HIV-1 neutralizing activity of CSF and plasma
using an in vitro assay. The observed trend towards reduced
glycosylation in CSF-derived viral sequences and near lack of
neutralizing activity in the CSF of our exploratory group of
six individuals offers strong support to the hypothesis that
reduced immune surveillance plays an important role in
driving the independent evolution of HIV-1 in the CNS.
The identification of a CSF-specific HIV-1 genetic
signature across compartmentalized individuals is strong evi-
dence that the viral quasi-species adapts to the local fitness
landscape within the CNS and, moreover, that commonal-
ities in this selective environment exist across individuals.
Position 308 (V3 loop position 13) was the most informative
sequence position, underscored by the overrepresentation of
proline and histidine at this position in the publicly available
CSF-derived sequence data. The presence of other residues
besides proline and histidine at this site in CSF-derived
sequences may result from the contribution of virus from
peripheral sources to CSF populations (Ellis et al., 2000). The
role of position 308 in HIV-1 neurotropism is highlighted
by its discordant entropy scores in CSF and plasma and by
the fact that it has been featured in the reports of
several independent studies over the last decade (Korber
et al., 1994; Power et al., 1994). In addition, the presence
of certain residues at position 308 has been associated with
macrophage tropism, which is most likely correlated with
microglial tropism due to the extensive similarities between
these cell types (Chesebro et al., 1996). Understanding the
relevance of this sequence position to neurotropism and
neuropathogenesis may be achieved by infecting in vitro
foetal brain aggregates (Trillo-Pazos et al., 2004) or micro-
glial cell cultures with genetically defined HIV-1 strains to
determine the fitness consequences associated with p308
polymorphisms.
Our exploration of the relationship between cognitive
deficit in the host and viral genetics suggests that V3 loop
sequence may be a genetic determinant of neurovirulence.
Table 3 Relationship between degree of cognitive deficit
and consensus residue at position 5 of the V3 loop in
CSF- and plasma-derived sequences
Individual p5-CSF p5-plasma GDS
R S S 3.5
S H N 2.88
B S S 2.13
E S S 1.41
O S N 1.4
A N N 1.28
P N N 1.18
Q N N 0.94
F N N 0.88
J N N 0.75
D N N 0.69
L N N 0.63
M N N 0.56
H G G 0.53
K N N 0.5
C N N 0.44
N G G 0.31
GDS = global deficit score. Individuals listed from highest to lowest
cognitive deficit.
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The contribution of V3 loop position 5 to neurovirulence
may result from accelerated pathogenesis due to improved
replicative capacity within the CNS (Ellis et al., 1997).
However, HIV-1 neurotropism and neurovirulence may be
distinct and separable phenomena (Power et al., 1995).
Although certain Env mutations may not enhance the repli-
cation kinetics of HIV-1 within the CNS, they may increase
gp160-mediated neurotoxicity due to alterations in intera-
ctions between virion surface glycoproteins and host cell
surface molecules (Lipton, 1992; Toggas et al., 1994;
Kanmogne et al., 2002). Several investigators have presented
evidence that residues elsewhere within the V3 loop may
influence HIV neuropathogenesis (Power et al., 1994;
Kuiken et al., 1995; Power et al., 1995). These data, taken
together, suggest that there may be multiple, independent
sequence pathways leading to HIV neurovirulence. More-
over, the extent of variation observed in subtype B V3
loop sequence is not observed in many other clades like
subtype C; therefore, the degree of neurotropism and
neurovirulence associated with non-B subtypes may differ,
as well as their genetic determinants.
There are limitations of this analysis as a result of
the specific clinical characteristics of the cohort studied.
While the cohort had a wide range of current CD4+ counts
(16–688), most had experienced advanced immunosuppres-
sion (CD4 nadir < 200) and were partially immune recon-
stituted on ART. Thus, our results may not be generalizable
to individuals with less advanced disease or those who have
never seen effective antiretroviral therapy. Additionally, the
cases were selected on the basis of having detectable CSF HIV
RNA levels, and therefore these results may not be represen-
tative of individuals with undetectable CSF viral loads.
The CNS has been characterized as a reservoir, a compart-
ment and a drug sanctuary (Foudraine et al., 1998; Gunthard
et al., 2001). Our investigations characterize the differing
selection pressures between the CSF and blood and docu-
ment a specific genetic signature of virus compartmentalized
in the CNS. These data offer important insights into the
adaptation of HIV to the CNS environment, which may
prove valuable in managing HIV-1 infection and preventing
the development of neurological disorders.
Supplementary material
Supplementary data are available at Brain Online.
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